Palatin Technologies, Inc.
AMEX:PTN · New York Stock Exchange American
-$0.10 today
Vol 0.01M · Avg 1.78M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
362.3%
avg 2587.5%
ROIC
378.5%
avg -389.6%
ROA
-529.8%
avg -142.8%
Analysis
ROIC is currently the strongest return metric at 378.5% versus its period average of -389.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Stephen T. Wills | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer & Secretary | $1.10M | — | 69 | $63,371.00 | 0.24% |
Carl Spana | Co-Founder, President, Chief Executive Officer & Director | $1.07M | — | 64 | $64,377.00 | 0.25% |
John Dodd | Senior Vice President of Preclinical Development | — | — | — | $27,281.00 | 0.10% |
Robert Jordan | Senior Vice President of Program Operations | — | — | — | $138,065.00 | 0.53% |
Stephen A. Slusher | Chief Legal Officer | — | — | — | $63,371.00 | 0.24% |
James E. Hattersley | Senior Vice President of Business Development | — | — | 66 | — | — |
Burns McClellan | Vice President of Investor Relations | — | — | — | — | — |
Michael Raizman | Chief Medical Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$9,460.53
Net Sentiment
$9,460.53
Net selling
Most Active
WILLS STEPHEN T
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $9,460.53 over the last 12 months. That adds up to net selling of $9,460.53. WILLS STEPHEN T was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +460.0% | +18.0% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +460.0% over three years. Forward estimates point to Revenue at +18.0% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Who manages PTN?
Palatin Technologies, Inc. (PTN) lists 8 active executives. The top listed executive is John Dodd, Senior Vice President of Preclinical Development.
Are PTN insiders buying or selling?
Recent insider activity shows net buying of $461.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.